Iatrogenic Adverse Events in the Coronary Care Unit

Slides:



Advertisements
Similar presentations
Ischemic Heart Disease Group of diseases Most common cause of death in developed countries Terminology: 1.Angina pectoris 2.Myocardial infarction 3.Sudden.
Advertisements

ACUTE CORONARY SYNDROME (ACS). ACS Pathophysiology is that of a ruptured or eroded atheromatous plaque. Pathophysiology is that of a ruptured or eroded.
Shock: Cycle “A” Refresher Shock Nature’s prelude to death 2008 Cycle “A” OEC Refresher.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship Between Operator Volume and Adverse.
Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.
Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Procedural Outcomes of Chronic Total Occlusion Percutaneous.
Trends in Hospitalizations and Outcomes for Acute Cardiovascular Disease and Stroke, 1999–2011CLINICAL PERSPECTIVE by Harlan M. Krumholz, Sharon-Lise T.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: U.S. Hospital Use of Echocardiography: Insights.
Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseClinical Perspective by Michael D. Ezekowitz, Rangadham.
Cardiac Causes of Maternal Death
Cavitary Lung Lesion in a Patient With Congestive Heart Failure
Pulmonary artery catheterization in acute coronary syndromes: Insights from the GUSTO IIb and GUSTO III trials  Mauricio G. Cohen, MD, Robert V. Kelly,
A. Iain McGhie, M.D., Richard A. Goldstein, M.D.  CHEST 
Copyright © 2015 by the American Osteopathic Association.
Women, Bleeding, and Coronary Intervention
Nat. Rev. Cardiol. doi: /nrcardio
Copyright © 2017 American Academy of Pediatrics.
Echocardiographic modalities for evaluation and risk stratification of heart failure patients. 3D indicates 3-dimensional; EF, ejection fraction; LA, left.
Influence of Body Mass Index on Long-Term Survival After Cardiac Catheterization  Barak Zafrir, MD, Ronen Jaffe, MD, Ronen Rubinshtein, MD, Basheer Karkabi,
Circ Cardiovasc Qual Outcomes
Comparison of the Short-Term Survival Benefit Associated With Revascularization Compared With Medical Therapy in Patients With No Prior Coronary Artery.
Circ Cardiovasc Qual Outcomes
Comparison of Triflusal and Aspirin for Prevention of Vascular Events in Patients After Cerebral Infarction by Jordi Matías-Guiu, José M. Ferro, José Alvarez-Sabín,
Circ Cardiovasc Interv
Prasugrel or ticagrelor selection by clinical factor and CYP2C19 phenotype status. Prasugrel or ticagrelor selection by clinical factor and CYP2C19 phenotype.
Circ Cardiovasc Qual Outcomes
Circ Cardiovasc Interv
Atrial Fibrillation and Mortality in Heart FailureClinical Perspective
Circ Arrhythm Electrophysiol
Six-month–adjusted survival after aortic valve replacement (AVR) for severe aortic stenosis (AS) stratified by procedure and preoperative ejection fraction.
by Salim Yusuf, and Sonia Anand
Circ Cardiovasc Interv
Circ Cardiovasc Qual Outcomes
Circ Cardiovasc Qual Outcomes
Unadjusted 3-year cumulative incidence of adverse events after saphenous vein graft (SVG) percutaneous coronary intervention (PCI) with embolic protection.
Circ Cardiovasc Qual Outcomes
Physician and Patient Influences on Provider Performance
Circ Cardiovasc Interv
A, Breakdown of frailty into its underlying causes, manifestations, and clinical outcomes separated by LVAD-responsive and LVAD-independent causes of frailty.
Circ Cardiovasc Qual Outcomes
by Thomas Monks, Martin Pitt, Ken Stein, and Martin James
Circ Cardiovasc Interv
Circ Cardiovasc Qual Outcomes
Influence of Cardiac Surgeon Report Cards on Patient Referral by Cardiologists in New York State After 20 Years of Public Reporting by David L. Brown,
Effect of Provider Volume on the Accuracy of Hospital Report Cards
by Johan Denollet, Angélique A. Schiffer, and Viola Spek
Attenuation of Rebound Ischemia After Discontinuation of Heparin Therapy by Glycoprotein IIb/IIIa Inhibition With Eptifibatide in Patients With Acute Coronary.
Circ Cardiovasc Qual Outcomes
Plasma VAP-1/SSAO Activity Predicts Intracranial Hemorrhages and Adverse Neurological Outcome After Tissue Plasminogen Activator Treatment in Stroke by.
Circ Cardiovasc Qual Outcomes
Mathematical representation of Bayes theorem.
Circ Cardiovasc Qual Outcomes
Circ Cardiovasc Qual Outcomes
Hazard ratio (HR) for mortality for a 1-kg/m2 increase in body mass index (BMI) across the range of baseline BMI among patients with acute ischemic stroke.
Circ Cardiovasc Interv
Role of the CHADS2 Score in Acute Coronary Syndromes
Laszlo Littmann, MD, PhD  The American Journal of Medicine 
EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.
STEMI-INITIAL PRESENTATION TIMING 2013 ACC/AHA GUIDELINES
Pulmonary artery catheterization in acute coronary syndromes: Insights from the GUSTO IIb and GUSTO III trials  Mauricio G. Cohen, MD, Robert V. Kelly,
Laszlo Littmann, MD, PhD  The American Journal of Medicine 
Recent advances in mechanical ventilation
Syncope: Outcomes and Conditions Associated with Hospitalization
On Statin Treatment to Prevent Sepsis in Dialysis Patients
Behnam N. Tehrani et al. JACC 2019;73:
Jeffrey S. Berger, et al. Circ Cardiovasc Qual Outcomes 2009;2:78-87
Algorithm for the investigation of patients with elevated cardiac troponin concentrations in the context of an alternative acute illness. Algorithm for.
Performance of the Manchester Acute Coronary Syndromes decision rule with high-sensitivity cardiac troponin T (hs-cTnT) as the reference standard for the.
Performance of the Manchester Acute Coronary Syndromes decision rule in the validation study. Performance of the Manchester Acute Coronary Syndromes decision.
Performance of the Manchester Acute Coronary Syndromes decision rule in the derivation study. Performance of the Manchester Acute Coronary Syndromes decision.
Presentation transcript:

Iatrogenic Adverse Events in the Coronary Care Unit by Sherali A. Rahim, Anita Mody, Jennifer Pickering, P.J. Devereaux, and Salim Yusuf Circ Cardiovasc Qual Outcomes Volume 2(5):437-442 September 15, 2009 Copyright © American Heart Association, Inc. All rights reserved.

Figure 1. Relative frequency of potentially preventable IAEs Figure 1. Relative frequency of potentially preventable IAEs. Each patient may have had more than one IAE. Six of 14 potentially preventable bleeding events were life-threatening, and 2 of 6 potentially preventable life-threatening bleeding events were intracranial hemorrhages. Figure 1. Relative frequency of potentially preventable IAEs. Each patient may have had more than one IAE. Six of 14 potentially preventable bleeding events were life-threatening, and 2 of 6 potentially preventable life-threatening bleeding events were intracranial hemorrhages. Acute coronary syndrome was defined as 2 of the following: ischemic chest pain or elevation of cardiac biomarkers or electrocardiographic changes compatible with ischemia or acute occlusion of artery during cardiac catheterization. The category “Other” included infections (4/15), congestive heart failure (2/15), pulmonary embolism (1/15), respiratory failure (1/15), pseudoaneurysm (1/15), stress test with contraindication (1/15), interhospital transfer delay (1/15), delirium (1/15), hypotension (1/15), coronary sinus dissection (1/15), and cardiogenic shock (1/15). Sherali A. Rahim et al. Circ Cardiovasc Qual Outcomes. 2009;2:437-442 Copyright © American Heart Association, Inc. All rights reserved.

Figure 2. Mortality rate and the proportion of deaths related to preventable and nonpreventable IAEs. Figure 2. Mortality rate and the proportion of deaths related to preventable and nonpreventable IAEs. Sherali A. Rahim et al. Circ Cardiovasc Qual Outcomes. 2009;2:437-442 Copyright © American Heart Association, Inc. All rights reserved.

Figure 3. Rahim–Devereaux classification and approach to IAEs. Sherali A. Rahim et al. Circ Cardiovasc Qual Outcomes. 2009;2:437-442 Copyright © American Heart Association, Inc. All rights reserved.